Cardiff Oncology, Inc.
CRDFDrugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 3 past
How CRDF's past catalysts played out
FOLFIRI
Metastatic Colorectal Cancer
Onvansertib
Colorectal Cancer
Cytarabine
Acute Myeloid Leukemia
Abiraterone
Metastatic Castration-Resistant Prostate Cancer
Nanoliposomal irinotecan
Pancreatic Ductal Adenocarcinoma
FOLFOX
Metastatic Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FOLFIRI | Phase 2 | Metastatic Colorectal Cancer | - | - |
Onvansertib | Phase 2 | Colorectal Cancer | - | - |
Cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Abiraterone | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
Nanoliposomal irinotecan | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
FOLFOX | Phase 2 | Metastatic Colorectal Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cardiff Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Cardiff Oncology, Inc.'s (CRDF) pipeline across Phase 2. Its lead program is FOLFIRI (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cardiff Oncology, Inc.'s next FDA catalyst?→
Cardiff Oncology, Inc.'s (CRDF) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRDF biotech catalysts?→
Add CRDF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cardiff Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.